BetterLife Pharma enlists support from Buchanan Comms

Healthcare Communications

BetterLife Pharma Inc. is an emerging biotechnology company that develops and commercialises non-hallucinogenic psychedelic therapeutic pharmaceuticals and drug delivery platform technologies. It develops drug candidates from a wide range of complementary interferon-based technologies that could work with the immune system to impede tumours to treat some cancers, and fight virus infections like human papillomavirus (HPV) and Covid-19. The company has now teamed up with Buchanan Communications Ltd, a financial and corporate communications consultancy based in the UK which is part of WPP plc., to support BetterLife in communicating its milestones and developments with the media, partners and investors, and educating the public about the benefits of psychedelic treatments. This collaboration follows the recent announcement that Buchanan is working with venture capitalists The Conscious Fund, a prominent investor in the psychedelic medicine sector, to support the development of psychedelic biotechnology companies.

BetterLife’s CEO, Ahmad Doroudian, said: “We are very keen on expanding our reach and sharing our story beyond the psychedelic sector, which today is still quite niche. We look forward to working with Buchanan, which has a track record of educating the public and private capital markets through creative and impactful strategic communications.”

“We look forward to working with Buchanan, which has a track record of educating the public and private capital markets through creative and impactful strategic communications“

Buchanan’s Henry Harrison-Topham, partner and head of the ‘Cannabis & Wellness’ team, said: “We are delighted to have been appointed financial communications adviser by BetterLife Pharma, which is at the forefront of this exciting growth sector. We look forward to sharing its investment proposition and growth prospects with generalist and specialist investors, while also educating the wider market of the potential of psychedelic medicine. We believe we are the ideal communications partner for this fledgling industry due to our ability to convey a company’s investment proposition to the public and private capital markets through creative and impactful strategic communications.”

See all the latest jobs in Healthcare Communications
Return to news